InGeneron, Inc.   Report issue

For profit Phase 1
Founded: Houston TX United States (2006)

Organization Overview

First Clinical Trial
2016
NCT02918136
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

InGeneron, Inc.

Active Ingredients

Drugs in Phase 1 Trials (2)

allogeneic adipose derived mesenchymal stem cell (1 trial)

cortisone acetate (cortone) (1 trial)

Drugs in Other Trials (1)

dexamethasone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rotator Cuff Injuries (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3